Researchers at Stanford and the Chan Zuckerberg Biohub have discovered cross reactive, broadly neutralizing human antibodies against all serotypes of dengue virus.
Stanford researchers have developed a method of reducing pulmonary hypertension (PH) in mammals by targeting FHIT (Fragile Histidine Triad), a gene not previously linked to PH but consistently reduced in blood of patients with pulmonary arterial hypertension (PAH).
Researchers in the Roncarolo have discovered transcription factors that enable the tracking and differentiation of type 1 T regulatory (Tr1) cells for the treatment of autoimmune conditions.
Genome editing of human hematopoietic stem and progenitor cells (HSPCs) has the potential to create a new class of medication for the treatment of inherited and acquired genetic diseases of the blood and immune system.
Stanford scientists have developed a trivalent CAR T cell that targets three proteins that are essential for self-renewal and differentiation of leukemic stem cells.
Current techniques for reconstructing images in positron emission tomography (PET) cannot correctly use events in which at least one photon of a pair has scattered in tissue (also known as scatter coincidence events).
Researchers at Stanford have developed a technique to quantitatively measure protein structure and interactions in living cells by protein "footprinting"—monitoring the solvent accessibility of each residue under different environmental conditions.
Researchers at Stanford have developed a method using expressed genetic barcodes to enable simultaneous lineage tracing and single cell profiling. Intratumor heterogeneity fosters tumor evolution which is a key contributor to therapeutic failure and the lethality of cancer.
Stanford researchers at the Bao Lab have designed and fabricated a highly stretchable, tough, and self-healable material with high fatigue resistance applicable for electronic (e-) skin devices.
High-grade serous ovarian cancer (HG-SOC) is the most lethal gynecologic malignancy, in large part because most patients present with late-stage disease and receive the same therapeutic regimen despite significant heterogeneity in disease and clinical response.